Praxis Precision Medicines

Praxis’ epilepsy drug hits in phase 2, sparking stock rise and plans for next trial
Fierce Biotech
Tue, 03/26/24 - 11:34 am
Praxis Precision Medicines
clinical trials
PRAX-628
epilepsy
6 Neuro Data Readouts to Watch in the First Half of 2024
BioSpace
Mon, 01/22/24 - 11:53 am
neurodegenerative disease
clinical trials
ALS
major depressive disorder
Huntington's disease
Sanofi
Denali Therapeutics
Intra-Cellular Therapies
lumateperone
Annexon Biosciences
Guillain-Barré Syndrome
ANX005
Wave Life Sciences
Praxis Precision Medicines
Praxis Shares Fall 48% Following Mixed Data for Essential Tremor Candidate
BioSpace
Mon, 03/6/23 - 11:13 am
Praxis Precision Medicines
ulixacaltamide
clinical trials
essential tremor
Praxis share price halved after essential tremor fail, but biotech still plans phase 3
Fierce Biotech
Fri, 03/3/23 - 10:04 am
Praxis Precision Medicines
clinical trials
essential tremors
ulixacaltamide
Praxis wields the axe as lead depression drug fails
Pharmaforum
Tue, 06/7/22 - 10:12 am
Praxis Precision Medicines
major depressive disorder
layoffs
restructuring
PRAX-114
FDA tells Praxis it can't move into the clinic just yet for a rare epilepsy drug
Endpoints
Fri, 04/29/22 - 10:45 am
Praxis Precision Medicines
FDA
clinical hold
epilepsy
PRAX-222
Four biotechs and a Matthew Roden-led SPAC price IPOs, raising a combined $528M
Endpoints
Fri, 10/16/20 - 12:16 pm
IPOs
biotech
SPAC
Matthew Roden
Praxis Precision Medicines
Tarsus Pharmaceuticals
Aligos Therapeutics
Kiromic Biopharma
Tumeric Acquisition
Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs
Xconomy
Mon, 09/28/20 - 10:27 pm
Praxis Precision Medicines
Aligos Therapeutics
Tarsus Therapeutics
IPOs
Praxis raises $110M to advance 3 clinical-phase CNS drugs
Fierce Biotech
Tue, 07/28/20 - 10:48 am
Praxis Precision Medicines
GABAA positive allosteric modulator
depression
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
Xconomy
Mon, 05/4/20 - 10:34 pm
Praxis Precision Medicines
epilepsy
R&D